Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regeneron's Eylea Soars, But Praluent Is Slow Out Of The Gate

This article was originally published in Scrip

Executive Summary

Regeneron Pharmaceuticals Inc. turned in a strong quarter for its ophthalmology blockbuster Eylea (aflibercept), and predicts 20% growth for the drug's fifth year on the market. But the attention-grabber out of its fourth quarter and full-year 2015 earnings report was the sluggish launch of PCSK9 inhibitor Praluent (alirocumab).






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts